Skip to main content

Advertisement

SpringerLink
Log in

Depression in Parkinson’s Disease

Pharmacological Characteristics and Treatment

  • Review Article
  • Disease Management
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Parkinson’s disease (PD) is a common neurological illness and various degrees of depression frequently complicate its course. Risk factors for developing depression with PD include right-sided hemiparkinsonism, akinesia, increased severity of disability, anxiety and psychosis. Onset of parkinsonism at a younger age, female gender and the use of levodopa are arguable risk factors. Depression may be difficult to diagnose in patients with PD because the signs of the 2 disorders overlap. In addition, patients with atypical PD more commonly have depression than patients with classical PD presentations.

Antidepressant response to antiparkinsonian treatment has been limited. Enhancement of catecholamine levels in the CNS by selegiline (deprenyl), a monoamine oxidase (MAO) type B inhibitor, has shown potential antidepressant as well as neuroprotective effects. Other MAO inhibitors have shown antidepressant efficacy in animal models but have not been well tolerated by patients with PD. A catechol-O-methyltransferase (COMT) inhibitor combined with an MAO inhibitor might synergistically maximise the levels of catecholamines in the CNS.

Antidepressant medications used in patients without PD include tricyclic antidepressants (TCAs) and selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs), but only TCAs have been carefully studied for their antidepressant effects in PD. Electroconvulsive therapy has proven efficacy as antidepressant therapy in patients with PD, and transcranial magnetic stimulation has provided temporary relief of depression under experimental conditions.

Adverse effects of polypharmacy in the attempted treatment of depression in patients with PD are common in the elderly. A ‘serotonin syndrome’ has occurred frequently enough to preclude the coadministration of selegiline with SSRIs or TCAs, and multiple interactions between antiparkinsonian and antidepressant medications further complicate treatment strategies in patients with PD.

An algorithmic approach to the pharmacological treatment of depression is described in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson’s disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49: 492–7

    PubMed  CAS  Google Scholar 

  2. Adams RD, Victor M. Principles of neurology. 4th ed. New York: McGraw-Hill, 1989

    Google Scholar 

  3. Harvey NS. Psychiatric disorders in parkinsonism: 1. Functional illnesses and personality. Psychosomatics 1986; 27: 91–103

    PubMed  CAS  Google Scholar 

  4. Friedenberg DL, Cummings JL. Parkinson’s disease, depression, and the on-off phenomenon. Psychosomatics 1989; 30: 94–9

    PubMed  CAS  Google Scholar 

  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1984

  6. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson’s disease: a community-based study. Arch Neurol 1996; 53: 175–9

    PubMed  CAS  Google Scholar 

  7. Rodin G, Voshart K. Depression in the medically ill: an overview. Am J Psychiatry 1986; 143: 695–705

    Google Scholar 

  8. Santamaria J, Tolosa E. Clinical subtypes of Parkinson’s disease and depression. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 217–8

    Google Scholar 

  9. Santamaria J, Tolosa E, Valle A. Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130–3

    PubMed  CAS  Google Scholar 

  10. Cole SA, Woodard JL, Juncos JL, et al. Depression and disability in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996; 8: 20–5

    PubMed  CAS  Google Scholar 

  11. Kostic VS, Filipovic SR, Lecic D, et al. Effect of age at onset on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 1265–7

    PubMed  CAS  Google Scholar 

  12. Starkstein SE, Berthier ML, Bolduc PL, et al. Depression in patients with early versus late onset of Parkinson’s disease. Neurology 1989; 39: 1441–5

    PubMed  CAS  Google Scholar 

  13. Wagner ML, Fedak MN, Sage JI, et al. Complications of disease and therapy: a comparison of younger and older patients with Parkinson’s disease. Ann Clin Lab Sci 1996; 26: 389–95

    PubMed  CAS  Google Scholar 

  14. Gibb WRG, Lees AJ. A comparison of clinical and pathological features of young- and old-onsetParkinson’s disease. Neurology 1988; 38: 1402–6

    PubMed  CAS  Google Scholar 

  15. Taylor AE, Saint-Cyr JA. Depression in Parkinson’s disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci 1990; 2: 92–8

    PubMed  CAS  Google Scholar 

  16. Brown R, Jahanshahi M. Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 1995; 65: 61–84

    PubMed  CAS  Google Scholar 

  17. Miyoshi K, Ueki A, Nagano O. Management of psychiatric symptoms of Parkinson’s disease. Eur Neurol 1996; 36Suppl. 1: 49–54

    PubMed  Google Scholar 

  18. Henderson S. Epidemiology of psychiatric disorders. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams and Wilkins, 1995: 2513–9

    Google Scholar 

  19. Barber J, Tomer R, Sroka H, et al. Does unilateral dopamine deficit contribute to depression? Psychiatry Res 1985; 15: 17–24

    PubMed  CAS  Google Scholar 

  20. Vogel H-P. Symptoms of depression in Parkinson’s disease. Pharmacopsychiatry 1982; 15: 192–6

    CAS  Google Scholar 

  21. Cummings JL. Neuropsychiatric complications of drug treatment of Parkinson’s disease. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 313–27

    Google Scholar 

  22. Shaw AM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson’s disease. Q J Med 1980; 49: 283–93

    PubMed  CAS  Google Scholar 

  23. Goodwin FK. Behavioral effects of L-dopa in man. Semin Psychiatry 1971; 3: 477–92

    PubMed  CAS  Google Scholar 

  24. Silver JM, Yudofsky SC. Drug treatment of depression in Parkinson’s disease. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 240–54

    Google Scholar 

  25. Cherington M. Parkinsonism, L-dopa and mental depression. J Am Geriatr Soc 1970; 18: 513–6

    PubMed  CAS  Google Scholar 

  26. Schiffer RB, Kurlan R, Rubin A, et al. Evidence for atypical depression in Parkinson’s disease. Am J Psychiatry 1988; 145: 1020–2

    PubMed  CAS  Google Scholar 

  27. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996; 8: 383–92

    PubMed  CAS  Google Scholar 

  28. Factor SA, Molho ES, Podskalny GD, et al. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115–38

    PubMed  CAS  Google Scholar 

  29. Menza MA, Rosen RC. Sleep in Parkinson’s disease: the role of depression and anxiety. Psychosomatics 1995; 36: 262–6

    PubMed  CAS  Google Scholar 

  30. Tandberg E, Larsen JP, Aarsland D, et al. Risk factors for depression in Parkinson disease. Arch Neurol 1997; 54: 625–30

    PubMed  CAS  Google Scholar 

  31. Troester AI, Paolo AM, Lyons KE, et al. The influence of depression on cognition in Parkinson’s disease: a pattern of impairment distinguishable from Alzheimer’s disease. Neurology 1995; 45: 672–5

    Google Scholar 

  32. Troester AI, Stalp LD, Paolo AM, et al. Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol 1995; 52: 1164–9

    Google Scholar 

  33. Kuzis G, Sabe L, Tiberti C, et al. Cognitive functions in major depression and Parkinson disease. Arch Neurol 1997; 54: 982–6

    PubMed  CAS  Google Scholar 

  34. Wertman E, Speedie L, Shemesh Z, et al. Cognitive disturbances in parkinsonian patients with depression. Neuropsych Neuropsychol Behav Neurol 1993; 6: 31–7

    Google Scholar 

  35. Taylor AE, Saint-Cyr JA, Lang AE, et al. Parkinson’s disease and depression. Brain 1986; 109: 279–92

    PubMed  Google Scholar 

  36. Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443–54

    PubMed  CAS  Google Scholar 

  37. Keshavan MS, David AS, Narayanen HS,et al. ‘On-off’ phenomena and manic-depressive mood shifts: case report. J Clin Psychiatry 1986; 47: 93–4

    PubMed  CAS  Google Scholar 

  38. Sandyk R. Locus ceruleus-pineal melatonin interactions and the pathogenesis of the ‘On-off’ phenomenon associated with mood changes and sensory symptoms in Parkinson’s disease. Int J Neurosci 1989; 49: 95–101

    PubMed  CAS  Google Scholar 

  39. Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 1990; 28: 57–64

    PubMed  CAS  Google Scholar 

  40. Bissessur S, Tissingh G, Wolters EC, et al. rCBF SPECT in Parkinson’s disease patients with mental dysfunction. J Neural Transm Suppl 1997; 50: 25–30

    PubMed  CAS  Google Scholar 

  41. Ring HA, Bench CJ, Trimble MR, et al. Depression in Parkinson’s disease: a positron emission study. Br J Psychiatry 1994; 165: 333–9

    PubMed  CAS  Google Scholar 

  42. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992; 55: 377–82

    PubMed  CAS  Google Scholar 

  43. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  44. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson’s disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994; 89: 242–51

    PubMed  CAS  Google Scholar 

  45. de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology 1997; 48: 1277–81

    PubMed  Google Scholar 

  46. Sano M, Mayeux R. Biochemistry of depression in Parkinson’s disease. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 229–39

    Google Scholar 

  47. Mayeux R, Stern Y, Williams JBW, et al. Clinical and biochemical features of depression in Parkinson’s disease. Am J Psychiatry 1986; 143: 756–9

    PubMed  CAS  Google Scholar 

  48. Frochtengarten ML, Villares JCB, Maluf E, et al. Depressive symptoms and the dexamethasone suppression test in parkinsonian patients. Biol Psychiatry 1987; 22: 386–9

    PubMed  CAS  Google Scholar 

  49. Rabey JM, Scharf M, Oberman Z, et al. Cortisol, ACTH, and beta-endorphin after dexamethasone administration in Parkinson’s dementia. Biol Psychiatry 1990; 27: 581–91

    PubMed  CAS  Google Scholar 

  50. Mayberg HS, Solomon DH. Depression in Parkinson’s disease: a biochemical and organic viewpoint. Adv Neurol 1995; 65: 49–60

    PubMed  CAS  Google Scholar 

  51. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology 1980; 30: 1326–30

    PubMed  CAS  Google Scholar 

  52. Fibiger HC. The neurobiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci 1984; 11: 105–7

    PubMed  CAS  Google Scholar 

  53. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson’s disease and the mood response to intravenous methylphenidate: possible role of the ‘hedonic’ dopamine synapse. J Neurol Neurosurg Psychiatry 1989; 52: 724–31

    PubMed  CAS  Google Scholar 

  54. Mayeux R, Stern Y, Cote L, et al. Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 1984; 34: 642–6

    PubMed  CAS  Google Scholar 

  55. Mayeux R, Stern Y, Sano M, et al. The relationship of serotonin to depression in Parkinson’s disease. Mov Disord 1988; 3: 237–44

    PubMed  CAS  Google Scholar 

  56. Wolfe N, Katz DI, Albert ML, et al. Neuropsychological profile linked to low dopamine in Alzheimer’s disease, major depression, and Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990; 53: 915–7

    PubMed  CAS  Google Scholar 

  57. Sano M, Stern Y, Cote L, et al. Depression in Parkinson’s disease: a biochemical model. J Neuropsychiatry Clin Neurosci 1990; 2: 88–92

    PubMed  CAS  Google Scholar 

  58. Schneider LS, Chui HC, Severson JA, et al. Decreased platelet 3H-imipramine binding in Parkinson’s disease. Biol Psychiatry 1988; 24: 348–51

    PubMed  CAS  Google Scholar 

  59. Cash R, Raisman R, Ploska A, et al. High and low affinity [3H]imipramine binding sites in control and parkinsonian brains. Eur J Pharmacol 1985; 117: 71–80

    PubMed  CAS  Google Scholar 

  60. D’Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer’s disease and Parkinson’s disease. Ann Neurol 1986; 22: 229–36

    Google Scholar 

  61. Raisman R, Cash R, Agid Y. Parkinson’s disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 1986; 36: 556–60

    PubMed  CAS  Google Scholar 

  62. Mena MA, Aguado EG, de Yebenes JG. Monoamine metabolites in human cerebrospinal fluid: HPLC/ED method. Acta Neural Scand 1984; 69: 218–25

    CAS  Google Scholar 

  63. Kostic VS, Djuricic BM, Covickovic-Sternic N, et al. Depression and Parkinson’s disease: possible role of serotonergic mechanisms. J Neural 1987; 234: 94–6

    CAS  Google Scholar 

  64. Chia LG, Cheng FC, Kuo JS. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson’s disease. J Neurol Sci 1993; 116: 125–34

    PubMed  CAS  Google Scholar 

  65. Bell IR, Amend D, Kaszniak AW, et al. Trait shyness in the elderly: evidence for an association with Parkinson’s disease in family members and biochemical correlates. J Geriatr Psychiatry Neurol 1995; 8: 16–22

    PubMed  CAS  Google Scholar 

  66. Menza MA, Mark MH. Parkinson’s disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci 1993; 6: 165–9

    Google Scholar 

  67. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol 1989; 287: 373–92

    PubMed  CAS  Google Scholar 

  68. Chan-Palay V. Depression and dementia in Parkinson’s disease: catecholamine changes in the locus ceruleus, a basis for therapy. Adv Neurol 1993; 60: 438–46

    PubMed  CAS  Google Scholar 

  69. Mindham RHS, Marsden CD, Parkes JD. Psychiatric symptoms during L-dopa therapy for Parkinson’s disease and their relationship to physical disability. Psychol Med 1976; 6: 23–33

    PubMed  CAS  Google Scholar 

  70. Jouvent R, Abensour P, Bonnet AM, et al. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. J Affect Disord 1983; 5: 141–5

    PubMed  CAS  Google Scholar 

  71. Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 1992; 31: 937–46

    PubMed  CAS  Google Scholar 

  72. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72: 394–7

    PubMed  CAS  Google Scholar 

  73. Huszonek JJ. Anticholinergic effects in a depressed parkinsonian patient. J Geriatr Psychiatry Neurol 1995; 8: 100–2

    PubMed  CAS  Google Scholar 

  74. Kuhn W, Muller T. The clinical potential of deprenyl in neurologic and psychiatric disorders. J Neural Transm Suppl 1996; 48: 85–93

    PubMed  CAS  Google Scholar 

  75. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978; 6: 542–4

    PubMed  CAS  Google Scholar 

  76. Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992; 42: 541–4

    PubMed  CAS  Google Scholar 

  77. Brown AS, Gershon S. Dopamine and depression. J Neural Transm 1993; 91: 75–109

    CAS  Google Scholar 

  78. Parkinson Study Group. Effect of deprenyl of the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–71

    Google Scholar 

  79. Przuntek H, Kuhn W, Kraus P. The effect of R-(−)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA, and HVA levels in the cerebrospinal fluid. Acta Neurol Scand Suppl 1989; 126: 153–6

    PubMed  CAS  Google Scholar 

  80. Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo parkinsonian patients: the French Selegiline Multicenter Trial. Mov Disord 1993; 8Suppl. 1: S36–40

    PubMed  Google Scholar 

  81. Hoffman WE. Treatment of major depression and Parkinson’s disease with combined phenelzine and amantadine [letter]. Am J Psychiatry 1985; 142: 273

    Google Scholar 

  82. Hargrave R, Ashford JW. Phenelzine treatment of depression in Parkinson’s disease. Am J Psychiatry 1992; 149: 1751–2

    PubMed  CAS  Google Scholar 

  83. Lavian G, Finberg JPM, Youdim MBH. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine. Clin Neuropharmacol 1993; 16Suppl. 2: S1–7

    PubMed  Google Scholar 

  84. Haefely W, Burkard WP, Cesura A, et al. Pharmacology of moclobemide. Clin Neuropharmacol 1993; 16Suppl. 2: S8–18

    PubMed  Google Scholar 

  85. Waldmeier PC, Glatt A, Jaekel J, et al. Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor. Clin Neuropharmacol 1993; 16Suppl. 2: S19–24

    PubMed  Google Scholar 

  86. Mannisto PT, Lang A, Rauhala P, et al. Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Eur J Pharmacol 1995; 274: 229–33

    PubMed  CAS  Google Scholar 

  87. Illi A, Sundberg S, Ojala-Karlsson P, et al. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996; 59: 450–7

    PubMed  CAS  Google Scholar 

  88. Klockgether T, Loschmann PA, Wullner U. New medical and surgical treatments for Parkinson’s disease. Curr Opin Neurol 1994; 7(4): 346–52

    PubMed  CAS  Google Scholar 

  89. Price LH, Spencer DD, Marek KL, et al. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson’s disease. Biol Psychiatry 1995; 38: 498–505

    PubMed  CAS  Google Scholar 

  90. Masterman DL, Bronstein J, DeSalles AF, et al. Cognitive and behavioral performance following unilateral ventroposterior pallidotomy. Neurology 1997; 48: A252–3

    Google Scholar 

  91. Warburton JW. Depressive symptoms in Parkinson’s patients referred for thalamotomy. J Neurol Neurosurg Neuropsychiatry 1967; 30: 368–70

    CAS  Google Scholar 

  92. Klaassen T, Verhey FRJ, Sneijders GHJM, et al. Treatment of depression in Parkinson’s disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995; 7: 281–6

    PubMed  CAS  Google Scholar 

  93. Mandell AJ, Markham C, Fowler W. Parkinson’s syndrome, depression and imipramine: a preliminary report. Calif Med 1961; 95: 12–4

    PubMed  CAS  Google Scholar 

  94. Denmark JC, David JDP, McComb SG. Imipramine hydrochloride (Tofranil) in parkinsonism: a preliminary report. Br J Clin Pract 1961; 15: 523–4

    PubMed  CAS  Google Scholar 

  95. Gillhespy RO, Mustard DM. The evaluation of imipramine in the treatment of Parkinson’s disease. Br J Clin Pract 1963; 17: 205–8

    PubMed  CAS  Google Scholar 

  96. Strang RR. Imipramine in treatment of parkinsonism: a double-blind placebo study. BMJ 1965; 2: 33–4

    PubMed  CAS  Google Scholar 

  97. Cunningham LA. Depression in the medically ill: choosing an antidepressant. J Clin Psychiatry 1994; 55Suppl. A: 90–7; discussion 98-100

    PubMed  Google Scholar 

  98. Drevets WC. Geriatric depression: brain imaging correlates and pharmacologie considerations. J Clin Psychiatry 1994; 55Suppl. A: 71–81; discussions 82, 98-100

    PubMed  Google Scholar 

  99. Stoudemire A. New antidepressant drugs and the treatment of depression in the medically ill patient. Psychiatr Clin North Am 1996; 19: 495–514

    PubMed  CAS  Google Scholar 

  100. McCance-Katz EF, Marek KL, Price LH. Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 1992; 42: 1813–4

    PubMed  CAS  Google Scholar 

  101. Steur ENHJ. Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–3

    PubMed  CAS  Google Scholar 

  102. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson’s disease, and the locus ceruleus. Clin Neuropharmacol 1986; 9: 373–8

    PubMed  CAS  Google Scholar 

  103. Fontaine R, Ontiveros A, Elle R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55: 234–41

    PubMed  CAS  Google Scholar 

  104. Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry 1996; 57Suppl. 2: 24–30

    PubMed  Google Scholar 

  105. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995; 10Suppl. 4: 25–35

    PubMed  Google Scholar 

  106. Marttila M, Jaaskelainen J, Jarvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995; 5: 441–6

    PubMed  CAS  Google Scholar 

  107. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurology 1984; 34: 1092–4

    PubMed  CAS  Google Scholar 

  108. Preskorn SH, Othmer SC. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 1984; 4: 20–34

    PubMed  CAS  Google Scholar 

  109. Martin P, Massol J, Puech AJ. Captopril as an antidepressant? Effects on the learned helplessness paradigm in rats. Biol Psychiatry 1990; 27: 968–74

    PubMed  CAS  Google Scholar 

  110. Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int J Biochem Cell Biol 1996; 28: 721–38

    PubMed  CAS  Google Scholar 

  111. Rasmussen KG, Abrams R. The role of electroconvulsive therapy in Parkinson’s disease. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: neurobehavioral aspects. New York: Oxford University Press, 1992: 255–70

    Google Scholar 

  112. Atre-Vaidya N, Jampala VC. Electroconvulsive therapy in parkinsonism with affective disorder. Br J Psychiatry 1988; 152: 55–8

    PubMed  CAS  Google Scholar 

  113. Douyon R, Serby M, Klutchko B, et al. ECT and Parkinson’s disease revisited: a ‘naturalistic’ study. Am J Psychiatry 1989; 146: 1451–5

    PubMed  CAS  Google Scholar 

  114. Holcomb HH, Sternberg DE, Heninger GR. Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems. Biol Psychiatry 1983; 18: 865–73

    PubMed  CAS  Google Scholar 

  115. Lebensohn ZM, Jenkins RB. Improvement of parkinsonism in depressed patients treated with ECT. Am J Psychiatry 1975; 132: 283–385

    PubMed  CAS  Google Scholar 

  116. Asnis G. Parkinson’s disease, depression, and ECT: a review and case study. Am J Psychiatry 1977; 134: 191–5

    PubMed  CAS  Google Scholar 

  117. Burke WJ, Peterson J, Rubin EH. Electroconvulsive therapy in the treatment of combined depression and Parkinson’s disease. Psychosomatics 1988; 29: 341–6

    PubMed  CAS  Google Scholar 

  118. Balldin J, Granerus A, Linstedt G, et al. Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms. J Neural Transm 1981; 52: 199–211

    PubMed  CAS  Google Scholar 

  119. Fromm GH. Observations on the effect of electroshock treatment on patients with parkinsonism. Bull Tulane Univ 1959; 18: 71–3

    CAS  Google Scholar 

  120. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov Disord 1991; 6: 293–303

    PubMed  CAS  Google Scholar 

  121. Figiel GS, Hassen MA, Zorumski C, et al. ECT-induced delirium in depressed patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1991; 3: 405–11

    PubMed  CAS  Google Scholar 

  122. Figiel GS, Coffey CE, Djang WT, et al. Brain magnetic resonance imaging findings in ECT-induced delirium. J Neuropsychiatry Clin Neurosci 1990; 2: 53–8

    PubMed  CAS  Google Scholar 

  123. George MS, Wassermann EM, Post RM. Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. J Neuropsychiatry Clin Neurosci 1996; 8: 373–82

    PubMed  CAS  Google Scholar 

  124. Sandyk R, Derpapas K. The effects of external pico Tesla range magnetic fields on the EEG in Parkinson’s disease. Int J Neurosci 1993; 70: 85–96

    PubMed  CAS  Google Scholar 

  125. Fischer PA, Baas H. Therapeutic efficacy of R-(−) deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm Suppl 1987; 25: 137–47

    PubMed  CAS  Google Scholar 

  126. Lees A, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson’s disease. Lancet 1977; II: 791–5

    Google Scholar 

  127. Hietanen MH. Selegiline and cognitive function in Parkinson’s disease. Acta Neurol Scand 1991; 84: 407–10

    PubMed  CAS  Google Scholar 

  128. Indaco A, Carrieri PD. Amitriptyline in the treatment of headache in patients with Parkinson’s disease. Neurology 1988; 38: 1720–2

    PubMed  CAS  Google Scholar 

  129. Boer BH, Erdman RAM, Onstenk HJVC, et al. Clomipramine, depresie en de ziekte van Parkinson. Tijdschr Psychiatr 1976; 28: 499–509

    Google Scholar 

  130. Laitinen L. Desipramine in treatment of Parkinson’s disease. Acta Neurol Scand 1969; 45: 109–13

    PubMed  CAS  Google Scholar 

  131. Bedard P, Parkes JD, Marsden CD. Nomifensine in Parkinson’s disease. Br J Clin Pharmacol 1977; 4Suppl. 2: 187S–90S

    PubMed  Google Scholar 

  132. Andersen J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa. Acta Neurol Scand 1980; 62: 210–9

    PubMed  CAS  Google Scholar 

  133. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined used of deprenyl and an antidepressant in Parkinson’s disease. Neurology 1997; 48: 1070–7

    PubMed  CAS  Google Scholar 

  134. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry 1997; 9: 7–13

    PubMed  CAS  Google Scholar 

  135. King SA. Pain in depression and Parkinson’s disease [letter]. Am J Psychiatry 1993; 150: 353–4

    PubMed  CAS  Google Scholar 

  136. Mayeux R, Williams JB, Stern Y, et al. Depression and Parkinson’s disease. Adv Neurol 1984; 40: 241–50

    PubMed  CAS  Google Scholar 

  137. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989; 46: 45–50

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, UCLA School of Medicine, Los Angeles, California, USA

    Tiffany Tom &  Jeffrey L. Cummings

  2. Neuropsychiatry and Neurobehavior Unit, Psychiatry Service, West Los Angeles Veterans Affairs Medical Center, Los Angeles, California, USA

    Tiffany Tom &  Jeffrey L. Cummings

  3. Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, California, USA

    Jeffrey L. Cummings

Authors
  1. Tiffany Tom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey L. Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tom, T., Cummings, J.L. Depression in Parkinson’s Disease. Drugs Aging 12, 55–74 (1998). https://doi.org/10.2165/00002512-199812010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199812010-00006

Keywords

Search

Navigation